Juliana Campos is a journalist specializing in medical and healthcare topics. Her work has been featured in publications such as Dermatology Advisor and MDPI. Juliana's articles cover a range of topics including clinical trials, disease treatments, drug developments, and updates in the medical field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Juliana Campos' focus on healthcare and pharmaceuticals, with an emphasis on scientific data and press releases, indicates a preference for pitches that align with these areas. She seems to prioritize coverage of clinical trials, therapeutic strategies, genetic disorders, medical research, and biotechnology.
Given her reliance on citing data and press releases in her articles, Juliana may be interested in receiving pitches related to new studies or findings backed by robust scientific evidence. Pitches featuring exclusive access to experts involved in groundbreaking research or those at the forefront of developing therapeutic strategies could resonate well with her coverage style.
As she focuses nationally on the United States, relevant sources should have insights into developments within the country's healthcare and pharmaceutical landscape.
This information evolves through artificial intelligence and human feedback. Improve this profile .
| Early, accurate prenatal diagnosis and personalized management are essential to better outcomes for neonates with achondroplasia , according
Bezuclastinib has shown promising results in the open label extension of the SUMMIT trial for nonadvanced systemic mastocytosis (SM).
| Which of the statements below about therapies for antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) are correct?
| Rilzabrutinib may be a promising and effective therapy for patients with primary immune thrombocytopenia (ITP) who are unresponsive or
| Disease-modifying treatment (DMT) may not be universally effective for all patients with primary progressive multiple sclerosis (PPMS), but
| The US Food and Drug Administration (FDA) has approved crinecerfont (Crenessity™) for the treatment of classic congenital adrenal
| Neonatal lupus syndrome (NLS), fetal and neonatal alloimmune thrombocytopenia (FNAIT), and hemolytic disease of the fetus and newborn (HDFN) are
| A recent retrospective study highlighted the importance of human leukocyte antigen (HLA)-matched platelet units in improving outcomes for
| Significant cardiovascular risks are associated with ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL) and small
| Which of the statements below about testing for systemic mastocytosis are correct?
(833) 317-6278 
